Manufacturer
Janssen
Contents
Bortezomib
Indication
Treatment of multiple myeloma and mantle cell lymphoma in patients who have received at least 1 prior therapy.
Instruction
Velcade is administered as a 3-5 sec bolus IV injection in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 8. In cycles 1-4, Velcade is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In cycles 5-9, Velcade is administered once weekly (days 1, 8, 22 and 29). At least 72 hrs should elapse between consecutive doses of Velcade.
Drug interaction
CYP450 3A4 inhibitors or inducers. Oral antidiabetic agents.
Malaysia
